We demonstrate that coating calcium sulfate with deacetylated chitosan enhances the elution profile of daptomycin by prolonging the period during which high concentrations of antibiotic are released. Coatings reduced initial bolus release of daptomycin by a factor of 10 to approximately 1000 µg/ml, and levels remained above 100 µg/ml for up to 10 days. Chitosan-coated and uncoated calcium sulfate implants with and without 15% daptomycin were evaluated in an experimental model of staphylococcal osteomyelitis through bacteriology scores, radiology, histopathology, and Gram staining. Significant reduction in bacteriology scores was observed for implants containing daptomycin and coated with chitosan compared with all the other groups. We confirm that the use of chitosan-coated calcium sulfate beads for local antibiotic delivery can be correlated with an improved therapeutic outcome following surgical debridement in the treatment of chronic osteomyelitis.
CiernyG III. Surgical treatment of osteomyelitis. Plast Reconstr Surg2011; 127(Suppl 1): 190S–204S.
2.
BradyRALeidJGCalhounJH. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol2008; 52: 13–22.
3.
WeissECZielinskaABeenkenKE. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrob Agent Chemother2009; 53: 4096–4102.
4.
RaoNCannellaBCrossettLS. A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections. Clin Orthopaed Relat Res2008; 466: 1343–1348.
5.
KluinOSvan der MeiHCBusscherHJ. Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis. Exp Opin Drug Deliv2013; 10: 341–351.
6.
ZalavrasCGPatzakisMJThordarsonDB. Infected fractures of the distal tibial metaphysis and plafond: achievement of limb salvage with free muscle flaps, bone grafting, and ankle fusion. Clin Orthopaed Relat Res2004; 427: 57–62.
7.
BeenkenKEBradneyLBellamyW. Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis. Antimicrob Agent Chemother2012; 56: 5839–5844.
8.
GitelisSBrebachGT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthopaed Surg2002; 10: 53–60.
9.
GogiaJSMeehanJPDi CesarePE. Local antibiotic therapy in osteomyelitis. Semin Plast Surg2009; 23: 100–107.
10.
RichelsophKCWebbNDHaggardWO. Elution behavior of daptomycin-loaded calcium sulfate pellets: a preliminary study. Clin Orthopaed Relat Res2007; 461: 68–73.
TurnerTMUrbanRMHallDJ. Local and systemic levels of tobramycin delivered from calcium sulfate bone graft substitute pellets. Clin Orthopaed Relat Res2005; 437: 97–104.
13.
von StechowDScaleDRauschmannMA. Minimizing the surgical approach in patients with spondylitis. Clin Orthopaed Relat Res2005; 439: 61–67.
14.
JayakumarRRamachandranRSudheesh KumarPT. Fabrication of chitin-chitosan/nano ZrO2 composite scaffolds for tissue engineering applications. Int J Biol Macromol2011; 49: 274–280.
15.
De CastroGPDowlingMBKilbourneM. Determination of efficacy of novel modified chitosan sponge dressing in a lethal arterial injury model in swine. J Trauma Acute Care Surg2012; 72: 899–907.
16.
PusateriAEMcCarthySJGregoryKW. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. J Trauma2003; 54: 177–182.
17.
NorowskiPACourtneyHSBabuJ. Chitosan coatings deliver antimicrobials from titanium implants: a preliminary study. Implant Dent2011; 20: 56–67.
18.
SmithJKBumgardnerJDCourtneyHS. Antibiotic-loaded chitosan film for infection prevention: a preliminary in vitro characterization. J Biomed Mater Res, Part B: Appl Biomater2010; 94: 203–211.
19.
FujimotoTTsuchiyaYTeraoM. Antibacterial effects of chitosan solution against Legionella pneumophila, Escherichia coli, and Staphylococcus aureus. Int J Food Microbiol2006; 112: 96–101.
20.
JarmilaVVavrikovaE. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities—a review. Curr Pharm Des2011; 17: 3596–3607.
21.
ChoYWChoYNChungSH. Water-soluble chitin as a wound healing accelerator. Biomaterials1999; 20: 2139–2145.
22.
PatelMPPatelRRPatelJK. Chitosan mediated targeted drug delivery system: a review. J Pharm Pharm Sci2010; 13: 536–557.
23.
StinnerDJNoelSPHaggardWO. Local antibiotic delivery using tailorable chitosan sponges: the future of infection control?J Orthopaed Trauma2010; 24: 592–597.
24.
WeissBDWeissECHaggardWO. Optimized elution of daptomycin from polymethylmethacrylate beads. Antimicrob Agent Chemother2009; 53: 264–266.
25.
SmeltzerMSThomasJRHickmonSG. Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthopaed Res1997; 15: 414–421.
26.
KanellakopoulouKPanagopoulosPGiannitsiotiE. In vitro elution of daptomycin by a synthetic crystallic semihydrate form of calcium sulfate, stimulan. Antimicrob Agent Chemother2009; 53: 3106–3107.
27.
WebbNDMcCanlessJDCourtneyHS. Daptomycin eluted from calcium sulfate appears effective against Staphylococcus. Clin Orthopaed Relat Res2008; 466: 1383–1387.
28.
ZhangYZhangM. Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J Biomed Mater Res2002; 62: 378–386.
29.
ZhaoJShenGLiuC. Enhanced healing of rat calvarial defects with sulfated chitosan-coated calcium-deficient hydroxyapatite/bone morphogenetic protein 2 scaffolds. Tissue Eng Part A2012; 18: 185–197.
30.
CuiXZhangBWangY. Effects of chitosan-coated pressed calcium sulfate pellet combined with recombinant human bone morphogenetic protein 2 on restoration of segmental bone defect. J Craniofac Surg2008; 19: 459–465.
31.
RevesBTBumgardnerJDColeJA. Lyophilization to improve drug delivery for chitosan-calcium phosphate bone scaffold construct: a preliminary investigation. J Biomed Mater Res, Part B: Appl Biomater2009; 90: 1–10.
32.
AbarrategiAMoreno-VicenteCRamosV. Improvement of porous beta-TCP scaffolds with rhBMP-2 chitosan carrier film for bone tissue application. Tissue Eng, Part A2008; 14: 1305–1319.
33.
Doty HA, Leedy MR, Courtney HS, et al. Composite chitosan and calcium sulfate scaffold for dual delivery of vancomycin and recombinant human bone morphogenetic protein-2. J Mater Sci Mater Med. Prepublished January 27, 2014. DOI:10.1007/s10856-014-5167-7.
34.
BuranapanitkitBSriniltaVIngvigaN. The efficacy of a hydroxyapatite composite as a biodegradable antibiotic delivery system. Clin Orthopaed Relat Res2004; 424: 244–252.
35.
BuranapanitkitBOungbhoKIngviyaN. The efficacy of hydroxyapatite composite impregnated with amphotericin B. Clin Orthopaed Relat Res2005; 437: 236–241.
36.
Di MartinoASittingerMRisbudMV. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials2005; 26: 5983–5990.
37.
ParkerACJenningsJABumgardnerJD. Preliminary investigation of crosslinked chitosan sponges for tailorable drug delivery and infection control. J Biomed Mater Res, Part B: Appl Biomater2013; 101: 110–123.
38.
SmithJKMoshrefARJenningsJA. Chitosan sponges for local synergistic infection therapy: a pilot study. Clin Orthopaed Relat Res2013; 471: 3158–3164.
MaderJTAdamsK. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agent Chemother1989; 33: 689–692.
41.
PoepplWTobudicSLingscheidT. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agent Chemother2011; 55: 4999–5003.
42.
NordenCW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis1988; 10: 103–110.
43.
CremieuxACCarbonC. Experimental models of bone and prosthetic joint infections. Clin Infect Dis Off Publ Infect Dis Soc Am1997; 25: 1295–1302.
44.
YinLYLazzariniLLiF. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother2005; 55: 995–1002.
45.
LazzariniLOvergaardKAContiE. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis?J Chemother2006; 18: 451–460.
46.
NelsonCLMcLarenSGSkinnerRA. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthopaed Res Off Publ Orthopaed Res Soc2002; 20: 643–647.
47.
WalshWRMorbergPYuY. Response of a calcium sulfate bone graft substitute in a confined cancellous defect. Clin Orthopaed Relat Res2003; 406: 228–236.
48.
TurnerTMUrbanRMGitelisS. Radiographic and histologic assessment of calcium sulfate in experimental animal models and clinical use as a resorbable bone-graft substitute, a bone-graft expander, and a method for local antibiotic delivery. One institution’s experience. J Bone Joint Surg Am Vol2001; 83A(Suppl 2(Pt 1)): 8–18.
49.
GitelisSPiaseckiPTurnerT. Use of a calcium sulfate-based bone graft substitute for benign bone lesions. Orthopedics2001; 24: 162–166.
50.
BorrelliJ JrPrickettWDRicciWM. Treatment of nonunions and osseous defects with bone graft and calcium sulfate. Clin Orthopaed Relat Res2003; 411: 245–254.
51.
ChoBCKimTGYangJD. Effect of calcium sulfate-chitosan composite: pellet on bone formation in bone defect. J Craniofac Surg2005; 16: 213–224; discussion 225–217.
52.
ChenHCuiXYuX. Effects of chitosan-coated pressed calcium sulfate pellets combined with recombinant human bone morphogenetic protein 2 on bone formation in femoral condyle-contained bone defects. J .Craniofac Surg2010; 21: 188–197.
53.
MuzzarelliRAMattioli-BelmonteMTietzC. Stimulatory effect on bone formation exerted by a modified chitosan. Biomaterials1994; 15: 1075–1081.
54.
MuzzarelliRAA. Chitosan composites with inorganics, morphogenetic proteins and stem cells, for bone regeneration. Carbohydr Polym2011; 83: 1433–1445.
55.
HamiltonVYuanYLRigneyDA. Bone cell attachment and growth on well-characterized chitosan films. Polym Int2007; 56: 641–647.
56.
LeedyMRMartinHJNorowskiPA. Use of chitosan as a bioactive implant coating for bone-implant applications. Chitosan Biomater II2011; 244: 129–165.
57.
BumgardnerJDWiserRGerardPD. Chitosan: potential use as a bioactive coating for orthopaedic and craniofacial/dental implants. J Biomater Sci Polym Ed2003; 14: 423–438.
58.
ZugravuMVSmithRARevesBT. Physical properties and in vitro evaluation of collagen-chitosan-calcium phosphate microparticle-based scaffolds for bone tissue regeneration. J Biomater Appl2013; 28: 566–579.
59.
ChesnuttBMYuanYBrahmandamN. Characterization of biomimetic calcium phosphate on phosphorylated chitosan films. J Biomed Mater Res Part A2007; 82: 343–353.
60.
ElderSGottipatiAZelenkaH. Attachment, proliferation, and chondroinduction of mesenchymal stem cells on porous chitosan-calcium phosphate scaffolds. Open Orthopaed J2013; 7: 275–281.
61.
WangJde BoerJde GrootK. Proliferation and differentiation of MC3T3-E1 cells on calcium phosphate/chitosan coatings. J Dent Res2008; 87: 650–654.
62.
ChoBCChungHYLeeDG. The effect of chitosan bead encapsulating calcium sulfate as an injectable bone substitute on consolidation in the mandibular distraction osteogenesis of a dog model. J Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg2005; 63: 1753–1764.
63.
RabeaEIBadawyMEStevensCV. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules2003; 4: 1457–1465.
64.
OngSYWuJMoochhalaSM. Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties. Biomaterials2008; 29: 4323–4332.
65.
RaafatDSahlHG. Chitosan and its antimicrobial potential—a critical literature survey. Microbiol Biotechnol2009; 2: 186–201.
66.
DaiTTanakaMHuangYY. Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Rev Anti-infect Ther2011; 9: 857–879.
67.
SimunekJBrandysovaVKoppovaI. The antimicrobial action of chitosan, low molar mass chitosan, and chitooligosaccharides on human colonic bacteria. Folia Microbiol2012; 57: 341–345.
68.
KimKWThomasRLLeeC. Antimicrobial activity of native chitosan, degraded chitosan, and O-carboxymethylated chitosan. J Food Protect2003; 66: 1495–1498.
